New hope for lung scarring? drug trial aims to slow breathing decline

This study tests two doses of an experimental drug, zampilimab, against a placebo in 240 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal is to see if the drug can improve lung function over 24 weeks, with an optional 24-week follow-up. Participants must be at least 40 years old and weigh 45 kg or more.